The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Regulatory News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.47
Bid: 1.45
Ask: 1.50
Change: -0.04 (-2.64%)
Spread: 0.05 (3.448%)
Open: 1.45
High: 1.47
Low: 1.448
Prev. Close: 1.515
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

17 Nov 2015 15:26

RNS Number : 0501G
Silver Falcon PLC
17 November 2015
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

SILVER FALCON PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Abdelatif LACHAB

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

17/11/2015

6. Date on which issuer notified:

17/11/2015

7. Threshold(s) that is/are crossed orreached: vi, vii

3%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Below 3%

Below 3%

2,300,000

2,300,000

3.54%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

2,300,000

3.54%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Abdelatif Lachab

15. Contact telephone number:

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLGGGPPGUPAGAM
Date   Source Headline
9th Mar 20212:00 pmRNSPrice Monitoring Extension
9th Mar 202111:00 amRNSPrice Monitoring Extension
9th Mar 20217:00 amRNSDirector/PDMR Shareholding
8th Mar 20217:00 amRNSH.C. Wainwright Investment Conference
3rd Mar 20217:00 amRNSHEMO-CAR-T Update
26th Feb 202110:05 amRNSTotal Voting Rights
25th Feb 20214:56 pmRNSConversion of Convertible Loan Notes
15th Feb 20214:41 pmRNSSecond Price Monitoring Extn
15th Feb 20214:36 pmRNSPrice Monitoring Extension
10th Feb 20217:00 amRNSAllotment of Shares
3rd Feb 20217:01 amRNSDraw Down Under Financing Facility Agreement
29th Jan 20212:24 pmRNSPublication of Prospectus
13th Jan 20217:00 amRNSUpdate on CDX Antibody Development
6th Jan 20213:53 pmRNSResult of General Meeting
5th Jan 20217:00 amRNSCAR-T Master Translational Agreement with Penn
8th Dec 20207:00 amRNSChange to Date of General Meeting
2nd Dec 20204:41 pmRNSSecond Price Monitoring Extn
2nd Dec 20204:36 pmRNSPrice Monitoring Extension
2nd Dec 202011:06 amRNSSecond Price Monitoring Extn
2nd Dec 202011:01 amRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSPosting of Circular
18th Nov 20204:41 pmRNSSecond Price Monitoring Extn
18th Nov 20204:36 pmRNSPrice Monitoring Extension
18th Nov 20202:06 pmRNSSecond Price Monitoring Extn
18th Nov 20202:01 pmRNSPrice Monitoring Extension
18th Nov 202010:39 amRNSFinancing Facility of up to £60 Million
27th Oct 20207:00 amRNSCDX Development Agreement Further Extension
19th Oct 20207:00 amRNSPresentation at the American Society of Hematology
6th Oct 20207:00 amRNSSAFE-HEMO-CAR-T Effective against AML in vitro
30th Sep 20207:00 amRNSInterim Results for the period ended 30 June 2020
22nd Sep 202012:52 pmRNSFurther re. Grant of Options
10th Sep 20204:40 pmRNSSecond Price Monitoring Extn
10th Sep 20204:35 pmRNSPrice Monitoring Extension
26th Aug 20202:06 pmRNSSecond Price Monitoring Extn
26th Aug 20202:00 pmRNSPrice Monitoring Extension
25th Aug 20204:40 pmRNSSecond Price Monitoring Extn
25th Aug 20204:35 pmRNSPrice Monitoring Extension
21st Aug 20209:52 amRNSGrant of Options
14th Aug 20207:00 amRNSPresentations at Cancer Immunotherapy Symposia
11th Aug 20207:00 amRNSCAR-T Agreement with University of Pennsylvania
31st Jul 20207:00 amRNSBroker's Research Note
20th Jul 20204:40 pmRNSSecond Price Monitoring Extn
20th Jul 20204:35 pmRNSPrice Monitoring Extension
20th Jul 20202:05 pmRNSSecond Price Monitoring Extn
20th Jul 20202:00 pmRNSPrice Monitoring Extension
14th Jul 202011:00 amRNSPrice Monitoring Extension
14th Jul 20209:06 amRNSSecond Price Monitoring Extn
14th Jul 20209:00 amRNSPrice Monitoring Extension
13th Jul 20204:36 pmRNSPrice Monitoring Extension
13th Jul 20203:16 pmRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.